A Phase 3 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Terminated at 21 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-27.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 25th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2007, is one of 20 in phase 3, and was the 11th registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 6 started in 2007.
This study's enrollment of 84 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Pharma, one of the names counted as UCB S.A.. Under that name alone:
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 22nd largest by enrollment of the 34 interventional ones that give a count, is one of 5 that started in 2007, is one of 19 in phase 3, and was the 13th registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this open-label extension is to assess the long-term effect of the 24-hour transdermal delivery of rotigotine on motor function, sleep quality, and nocturnal and non-motor symptoms of Parkinson's disease. The long-term safety and tolerability of the rotigotine transdermal patch will also be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Rotigotine Transdermal Patch
Drug: Rotigotine
Rotigotine transdermal patches: 10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h) Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h
Also known as: Neupro®
Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance)
The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the elements in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. Baseline is defined as first titration visit (T1) of SP915.
Time frame: Baseline (baseline SP915) and week 13 (End of maintenance)
Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance)
The Parkinson Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores range between 0= never and 4= very often. Baseline is defined as Visit 2 of previous double- blind trial SP889.
Time frame: Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance)
Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep. Baseline is defined as Visit 2 of previous double- blind trial SP889.
Time frame: Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance)
The change in number of nocturias was used to evaluate improvements in sleep disorders. Baseline is defined as Visit 2 of previous double- blind trial SP889.
Time frame: Baseline (baseline SP889 NCT00474058) and week 13 (End of maintenance)
A total of 84 subjects belong to the Enrolled Set (ES) and all of them received at least 1 dose of trial medication, so they all belong to the Safety Set (SS). 83 subjects belong to the Full Analysis Set (FAS).
| Milestone | Rotigotine |
|---|---|
| Started | 84 |
| Completed | 66 |
| Not completed | 18 |
| Withdrew: Adverse event | 11 |
| Withdrew: Withdrawal by subject | 5 |
| Withdrew: Lost to follow-up | 2 |
The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the elements in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. Baseline is defined as first titration visit (T1) of SP915.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline in UPDRS III Score at Week 13 (End of Maintenance) | -5.8 ± 9.4 |
The Parkinson Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep and nocturnal disability in Parkinson´s disease. The item- scores range between 0= never and 4= very often. Baseline is defined as Visit 2 of previous double- blind trial SP889.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline in Parkinson Disease Sleep Scale (PDSS) at Week 13 (End of Maintenance) | -5.8 ± 7.8 |
Subjects were asked to assess nocturnal akinesia, dystonia and cramps, using an ordinal severity scale. While a score of 0= normal and 4= maximal severity, subjects could also rate their symptoms with values of 0.5, 1.5, 2.5, 3.5. The nocturnal akinesia score was used to evaluate motor performance while the dystonia and cramps scores were used to evaluate sleep. Baseline is defined as Visit 2 of previous double- blind trial SP889.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline in Nocturnal Akinesia, Dystonia, and Cramps Score (NADCS) at Week 13 (End of Maintenance) | -1.5 ± 2.1 |
The change in number of nocturias was used to evaluate improvements in sleep disorders. Baseline is defined as Visit 2 of previous double- blind trial SP889.
| Nocturias | Rotigotine |
|---|---|
| Change From Baseline in Number of Nocturias at Week 13 (End of Maintenance) | -0.4 ± 1.2 |
Collected over Adverse Events (AEs) were collected over the whole trial period from Visit 1 to the Safety Follow- Up Visit.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 16/84 (19%) | 55/84 (65.5%) |
| Event | Rotigotine |
|---|---|
| Femoral neck fractureInjury, poisoning and procedural complications | 3/84 |
| Atrial fibrillationCardiac disorders | 1/84 |
| Atrioventricular block third degreeCardiac disorders | 1/84 |
| VomitingGastrointestinal disorders | 1/84 |
| Reflux oesophagitisGastrointestinal disorders | 1/84 |
| Inguinal herniaGastrointestinal disorders | 1/84 |
| Application site vesiclesGeneral disorders | 1/84 |
| Chest painGeneral disorders | 1/84 |
| DeathGeneral disorders | 1/84 |
| OsteomyelitisInfections and infestations | 1/84 |
| Event | Rotigotine |
|---|---|
| SomnolenceNervous system disorders | 11/84 |
| HallucinationPsychiatric disorders | 11/84 |
| NauseaGastrointestinal disorders | 10/84 |
| Application site erythemaGeneral disorders | 10/84 |
| FallInjury, poisoning and procedural complications | 10/84 |
| DyskinesiaNervous system disorders | 9/84 |
| DizzinessNervous system disorders | 9/84 |
| Application site pruritusGeneral disorders | 8/84 |
| Oedema peripheralGeneral disorders | 8/84 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 8/84 |
| Age, Categorical(Participants) | Rotigotine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 34 |
| >=65 years | 49 |
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 66.2 ± 10.4 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 26 |
| Male | 57 |
| Race (NIH/OMB)(Participants) | Rotigotine |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 71 |
| More than one race | 0 |
| Unknown or Not Reported | 9 |
| L- Dopa(participants) | Rotigotine |
|---|---|
| Early | 10 |
| Advanced | 73 |
| Body Mass Index (BMI)(kg/ m^2) | Rotigotine |
|---|---|
| Mean | 26.928 ± 4.219 |
| Height(cm) | Rotigotine |
|---|---|
| Mean | 170.1 ± 10.58 |
| Weight(kg) | Rotigotine |
|---|---|
| Mean | 78.3 ± 16.6 |
The record gives a start of Jul 2007, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine